Marla Dubinsky, MD

Icahn School of Medicine at Mount Sinai

Poster(s):

• P0848 - Mirikizumab Effect on Bowel Urgency Resolution in a Randomized Controlled Phase 3 Trial of Participants With Crohn’s Disease
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0849 - Corticosteroid-Free Remission Through 3 Years of Upadacitinib Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 Long-Term Extension Study U-ACTIVATE
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0850 - Effect of Upadacitinib Treatment on Hematological Parameters in Patients With Moderate to Severe Active Crohn’s Disease or Ulcerative Colitis: Pooled Analysis of Phase 3 Induction and Maintenance Studies
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0851 - The Urgency Numeric Rating Scale: Psychometric Evaluation in Adults With Crohn’s Disease
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0852 - Etrasimod for Moderately to Severely Active Crohn’s Disease: Results From the Extension Period of a Phase 2 Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0853 - Low Incidence of Macular Edema in Patients in the Etrasimod Clinical Program
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0854 - The Hidden Burden of Fatigue in Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis: Results From the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET